Using a computer tool to find lung cancer relapse risk
Part of Cancer, Lungs & breathing clinical trials.
This study uses a machine-learning computer method to identify people with early-stage lung cancer who have a higher risk of the cancer coming back after surgery. If you qualify, your information may help researchers improve how doctors predict relapse and plan follow-up care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Have early-stage non-small-cell lung cancer
- Be scheduled for or have had surgical removal of the lung cancer
- Be able to understand the study and sign consent
- Have health insurance coverage for care
- Be free of other cancers diagnosed in the last 5 years
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether checking for tiny traces of cancer left in the blood (called minimal residual disease) after treatment can tell if lung cancer might come back. It may help doctors decide how often to monitor patients in the future.
This study looks at tiny particles from the body (including from lung samples) to see if they can predict whether non-small cell lung cancer comes back after surgery. It may help doctors identify people at higher risk of recurrence sooner, so follow-up plans can be better tailored.
This study tests a new way to predict if non-small cell lung cancer will return after surgery. You will give blood samples to look for cancer cells, and the team will build a model to help plan better follow-up care.
This trial looks at information and tissue from people with stage I to stage IIIA non-small cell lung cancer (NSCLC) who have surgery, sometimes with chemotherapy before surgery. Researchers want to understand why cancers come back (resistance) and how to better target treatments later.
This study checks whether a special blood test (ctDNA) taken before and after surgery can predict whether non-small cell lung cancer will come back. If it works, it may help doctors spot recurrence earlier and guide follow-up care after tumor removal.
This trial uses a blood test to look for tiny bits of cancer DNA after treatment. It may help find early signs that lung cancer has come back, so doctors can act sooner.
Hear when a new Stage IIIA Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.